Table 3 Prognostic role of the expression of each immune marker separately in tumor cells and immune cells

In tumor cells

PD-1

Negative (N = 227)

85.5

–

92.5

–

Positive (N = 0)

0

0

PD-L1

Negative (N = 181)

83.4

0.081

91.7

0.348

Positive (N = 46)

93.5

95.7

PD-L2

Negative (N = 30)

90.0

0.494

96.7

0.378

Positive (N = 197)

84.8

91.9

IDO

Negative (N = 98)

84.7

0.640

89.8

0.145

Positive (N = 129)

86.0

94.6

TIM3

Negative (N = 118)

83.9

0.538

94.1

0.369

Positive (N = 109)

87.2

90.8

OX40

Negative (N = 145)

89.7

0.025

94.5

0.181

Positive (N = 82)

78.0

89.0

OX40L

Negative (N = 141)

87.9

0.224

93.6

0.475

Positive (N = 86)

81.4

90.7

B7-H2

Negative (N = 34)

97.1

0.054

94.1

0.782

Positive (N = 193)

83.4

92.2

In immune cells

PD-1

Negative (N = 101)

80.2

0.040

90.1

0.208

Positive (N = 126)

89.7

94.4

PD-L1

Negative (N = 136)

80.9

0.020

90.4

0.163

Positive (N = 91)

92.3

95.6

PD-L2

Negative (N = 119)

81.5

0.086

90.8

0.296

Positive (N = 108)

89.8

94.4

IDO

Negative (N = 73)

84.9

0.823

93.2

0.882

Positive (N = 154)

85.7

92.2

TIM3

Negative (N = 123)

82.1

0.100

90.2

0.149

Positive (N = 104)

89.4

95.2

OX40

Negative (N = 143)

84.6

0.564

91.6

0.452

Positive (N = 84)

86.9

94.0

OX40L

Negative (N = 124)

80.6

0.020

90.3

0.157

Positive (N = 103)

91.3

95.1

B7-H2

Negative (N = 77)

83.1

0.502

90.9

0.523

Positive (N = 150)

86.7

93.3